BH3 mimetics as potential treatment for AML
Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow
The iwCLL 2017 meeting
Immunotherapy highlights in multiple myeloma at ASH 2016
Niels van de Donk